BioSpaceOriginal article
BioVie shares halve on murky Parkinson’s disease readout
Phase 2MixedNegative
AI Analysis
Summary
BioVie's Parkinson's disease mid-stage trial showed mixed results, with the company declaring success based on an alternative endpoint rather than the FDA-submitted primary endpoint, resulting in a nearly 50% stock decline reflecting market concern.
Clinical Trial Data
Phase
Phase_2
Outcome Details
Company claimed victory using alternative endpoint to the one submitted to FDA; significant stock decline suggests market skepticism
Importance:6/10
Sentiment:
-0.80
Parkinson's diseasemid-stage trialstock declineregulatory concernendpoint discrepancy
Related Companies
Read the original article
Published by BioSpace on August 6, 2026 6:31 PM